Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $17,362 | $98,225 | $490,727 | $148,591 |
| - Cash | $17,909 | $77,605 | $24,194 | $28,551 |
| + Debt | $2,481 | $3,123 | $40,164 | $2,632 |
| Enterprise Value | $1,934 | $23,743 | $506,697 | $122,672 |
| Revenue | $19,632 | $14,919 | $9,834 | $26,544 |
| % Growth | 31.6% | 51.7% | -63% | – |
| Gross Profit | -$40,041 | -$59,206 | $9,834 | $26,459 |
| % Margin | -204% | -396.8% | 100% | 99.7% |
| EBITDA | -$56,825 | -$85,894 | -$56,188 | -$8,524 |
| % Margin | -289.5% | -575.7% | -571.4% | -32.1% |
| Net Income | -$60,477 | -$86,879 | -$61,226 | -$336 |
| % Margin | -308.1% | -582.3% | -622.6% | -1.3% |
| EPS Diluted | -1.46 | -2.59 | -1.52 | -1.01 |
| % Growth | 43.6% | -70.4% | -50.5% | – |
| Operating Cash Flow | -$59,917 | -$81,177 | -$7,566 | -$37,328 |
| Capital Expenditures | -$123 | -$1,132 | -$4,660 | -$1,871 |
| Free Cash Flow | -$60,040 | -$82,309 | -$12,226 | -$39,199 |